Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01612546 · ClinicalTrials.gov registry record · Phase 2
Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery
A Phase 2 study of Adenocarcinoma of the Gastroesophageal Junction and Recurrent Gastric Cancer, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT01612546 is a Phase 2 study of Adenocarcinoma of the Gastroesophageal Junction and Recurrent Gastric Cancer that has completed, run by City of Hope Medical Center. The registered enrollment target is 10 participants, below the 91-participant average among 7 other Adenocarcinoma of the Gastroesophageal Junction trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01612546, a Phase 2 study of Adenocarcinoma of the Gastroesophageal Junction and Recurrent Gastric Cancer, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot clinical trial studies cyclodextrin-based nanopharmaceutical CRLX101 in treating patients with advanced or metastatic stomach, gastroesophageal, or esophageal cancer that has progressed through at least one prior regimen of chemotherapy and cannot be removed by surgery. CRLX101 delivers the cytotoxic topoisomerase-1 inhibitor camptothecin into tumor cells and is hypothesized to interrupt the growth of tumor cells.
Conditions Studied
Interventions
- OTHER Laboratory biomarker analysis
- DRUG cyclodextrin-based polymer-camptothecin CRLX101
- OTHER Pharmacological studies
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-11 |
| Est. Completion | 2015-01-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01612546
The ClinicalTrials.gov registry entry for NCT01612546 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 91-participant average among 7 other Adenocarcinoma of the Gastroesophageal Junction trials with a reported enrollment target (89% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Adenocarcinoma of the Gastroesophageal Junction appearing as the primary indexed condition, and to 3 interventions - of which Laboratory biomarker analysis is the first listed.
NCT01612546 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01612546 about?
NCT01612546 is a clinical study titled "Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery". This pilot clinical trial studies cyclodextrin-based nanopharmaceutical CRLX101 in treating patients with advanced or metastatic stomach, gastroesophageal, or esophageal cancer that has progressed through at least one prior regimen of chemotherapy and cannot be removed by surgery. CRLX101 delivers t...
What is the current status of trial NCT01612546?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2012-11. Estimated completion is 2015-01-15.
What conditions does trial NCT01612546 study?
This clinical trial studies the following conditions: Adenocarcinoma of the Gastroesophageal Junction, Recurrent Gastric Cancer, Stage IIIB Gastric Cancer, Adenocarcinoma of the Esophagus, Squamous Cell Carcinoma of the Esophagus.
What interventions are being tested in trial NCT01612546?
The interventions under investigation include: Laboratory biomarker analysis (OTHER), cyclodextrin-based polymer-camptothecin CRLX101 (DRUG), Pharmacological studies (OTHER).
Who is sponsoring clinical trial NCT01612546?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01612546 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma of the Gastroesophageal Junction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Induction FLOT With CROSS CRT for Esophageal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
COMPLETED · Phase 2
-
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
COMPLETED · Phase 2
-
Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer
COMPLETED · Phase 2
-
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
COMPLETED · Phase 2
-
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
COMPLETED · Phase 1
Explore more on PlainTrial
Adenocarcinoma of the Gastroesophageal Junction
All registered trials for this condition
Recurrent Gastric Cancer
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.